These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 31367876)
1. Sugar Modification Enhances Cytotoxic Activity of PAMAM-Doxorubicin Conjugate in Glucose-Deprived MCF-7 Cells - Possible Role of GLUT1 Transporter. Sztandera K; Działak P; Marcinkowska M; Stańczyk M; Gorzkiewicz M; Janaszewska A; Klajnert-Maculewicz B Pharm Res; 2019 Jul; 36(10):140. PubMed ID: 31367876 [TBL] [Abstract][Full Text] [Related]
2. A robust pH-sensitive unimolecular dendritic nanocarrier that enables targeted anti-cancer drug delivery via GLUT transporters. Kumar P; Paknikar KM; Gajbhiye V Colloids Surf B Biointerfaces; 2018 Nov; 171():437-444. PubMed ID: 30075419 [TBL] [Abstract][Full Text] [Related]
3. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery. Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851 [TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-hepatocarcinoma efficacy by GLUT1 targeting and cellular microenvironment-responsive PAMAM-camptothecin conjugate. Ma P; Sun Y; Chen J; Li H; Zhu H; Gao X; Bi X; Zhang Y Drug Deliv; 2018 Nov; 25(1):153-165. PubMed ID: 29282992 [TBL] [Abstract][Full Text] [Related]
5. Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer. Fu F; Wu Y; Zhu J; Wen S; Shen M; Shi X ACS Appl Mater Interfaces; 2014 Sep; 6(18):16416-25. PubMed ID: 25185074 [TBL] [Abstract][Full Text] [Related]
6. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609 [TBL] [Abstract][Full Text] [Related]
7. The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers. Zhong Q; Humia BV; Punjabi AR; Padilha FF; da Rocha SRP Eur J Pharm Sci; 2017 Nov; 109():86-95. PubMed ID: 28774811 [TBL] [Abstract][Full Text] [Related]
8. Core-shell tecto dendrimers formed via host-guest supramolecular assembly as pH-responsive intelligent carriers for enhanced anticancer drug delivery. Wang J; Li D; Fan Y; Shi M; Yang Y; Wang L; Peng Y; Shen M; Shi X Nanoscale; 2019 Nov; 11(46):22343-22350. PubMed ID: 31728477 [TBL] [Abstract][Full Text] [Related]
9. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells. He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067 [TBL] [Abstract][Full Text] [Related]
10. In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate. Mohammed AFA; Higashi T; Motoyama K; Ohyama A; Onodera R; Khaled KA; Sarhan HA; Hussein AK; Arima H AAPS J; 2019 Apr; 21(4):54. PubMed ID: 30993472 [TBL] [Abstract][Full Text] [Related]
11. [Inhibition of MCF-7/ADR cells by DOX-loaded pluronic-attached PAMAM dendrimer conjugate]. Gu ZJ; Wang M; Fang QY; Wang CR; Zheng HY Yao Xue Xue Bao; 2014 Aug; 49(8):1188-93. PubMed ID: 25322563 [TBL] [Abstract][Full Text] [Related]
12. Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release. Thanh VM; Nguyen TH; Tran TV; Ngoc UP; Ho MN; Nguyen TT; Chau YNT; Le VT; Tran NQ; Nguyen CK; Nguyen DH Mater Sci Eng C Mater Biol Appl; 2018 Jan; 82():291-298. PubMed ID: 29025661 [TBL] [Abstract][Full Text] [Related]
13. Co-administration of a charge-conversional dendrimer enhances antitumor efficacy of conventional chemotherapy. Cao J; Wang C; Guo L; Xiao Z; Liu K; Yan H Eur J Pharm Biopharm; 2018 Jun; 127():371-377. PubMed ID: 29499301 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of stimuli-responsive vesicle from PEGylated hyperbranched PAMAM-doxorubicin conjugate for gastric cancer therapy. Nie J; Wang Y; Wang W Int J Pharm; 2016 Jul; 509(1-2):168-177. PubMed ID: 27234696 [TBL] [Abstract][Full Text] [Related]
15. Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery. Wang G; Fu L; Walker A; Chen X; Lovejoy DB; Hao M; Lee A; Chung R; Rizos H; Irvine M; Zheng M; Liu X; Lu Y; Shi B Biomacromolecules; 2019 May; 20(5):2148-2158. PubMed ID: 30995832 [TBL] [Abstract][Full Text] [Related]
16. Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modified multi-walled carbon nanotubes. Wen S; Liu H; Cai H; Shen M; Shi X Adv Healthc Mater; 2013 Sep; 2(9):1267-76. PubMed ID: 23447549 [TBL] [Abstract][Full Text] [Related]
17. Novel water-soluble and pH-responsive anticancer drug nanocarriers: doxorubicin-PAMAM dendrimer conjugates attached to superparamagnetic iron oxide nanoparticles (IONPs). Chang Y; Meng X; Zhao Y; Li K; Zhao B; Zhu M; Li Y; Chen X; Wang J J Colloid Interface Sci; 2011 Nov; 363(1):403-9. PubMed ID: 21821262 [TBL] [Abstract][Full Text] [Related]
18. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance. Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761 [TBL] [Abstract][Full Text] [Related]
19. Poly(ethylene glycol)-modified PAMAM-Fe3O4-doxorubicin triads with the potential for improved therapeutic efficacy: generation-dependent increased drug loading and retention at neutral pH and increased release at acidic pH. Nigam S; Chandra S; Newgreen DF; Bahadur D; Chen Q Langmuir; 2014 Feb; 30(4):1004-11. PubMed ID: 24446987 [TBL] [Abstract][Full Text] [Related]
20. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy. Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]